Topoisomerase i inhibitor SN-38 effectively attenuates growth of human non-small-cell lung cancer cell lines in vitro and in vivo

Journal of Environmental Pathology, Toxicology and Oncology

Volumn 30, Issue 1, 2011, Pages 1-10

  Maurya, Dharmendra Kumar ^a   Ayuzawa, Rie ^a   Doi, Chiyo ^a   Troyer, Deryl ^a   Tamura, Masaaki ^a  

^a KANSAS STATE UNIVERSITY   (United States)

Author keywords

Adenocarcinoma; Apoptosis; Cell cycle arrest; Mitochondrial membrane potential; SN 38

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; CASPASE 3; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE;

ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; FEMALE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LEWIS CARCINOMA; LUNG NON SMALL CELL CANCER; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR XENOGRAFT;

EID: 79960044955     PISSN: 07318898     EISSN: None     Source Type: Journal    
DOI: 10.1615/JEnvironPatholToxicolOncol.v30.i1.10     Document Type: Article

References (41)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225-49.
2. Johnson DH, Schiller JH. Novel therapies for the treatment of non-small cell lung cancer. Cancer Chemother Biol Response Modif. 2002;20:763-86.
3. Lynch TJ, Adjei AA, Bunn PA Jr, DuBois RN, Gandara DR, Giaccone G et al. Novel agents in the treatment of lung cancer: conference summary statement. Clin. Cancer Res. 2004;10:4199s-4204s.
4. Hsiang YH, Hertzberg R, Hecht S, Liu LF. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem. 1985;260:14873-8.
5. Hsiang Y-H, Liu, L. F. Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res. 1988;48:1722-6.
6. Kawato Y, Aonuma M, Hirota Y, Kuga H, Sato K. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res. 1991;51:4187-91.
7. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P et al., Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet. 2000;355:1041-7.
8. Noda K, Nishiwaki Y, Kawahara M, Negoro S, Sugiura T, Yokoyama A et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med. 2002;346:85-9.
9. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-42.
10. Fukuoka M, Furuse K, Saijo N, Nishiwaki Y, Ikegami H, Tamura T et al. Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. J Natl Cancer Inst. 1991;83:855-61.
11. Roth BJJ, D.H. Einhorn, L.H. et al. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol. 1992;10:282-91.
12. Ihde DC. Chemotherapy of lung cancer. N Engl J Med. 1992;327:1434-41.
13. Aisner J. Extensive-disease small-cell lung cancer: the thrill of victory: the agony of defeat. J Clin Oncol. 1996;14:658-65.
14. Masuda N, Fukuoka M, Kusunoki Y, Matsui K, Takifuji N, Kudoh S et al. CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol. 1992;10:1225-9.
15. Alexandre J, Hu Y, Lu W, Pelicano H, Huang P. Novel action of paclitaxel against cancer cells: bystander effect mediated by reactive oxygen species. Cancer Res. 2007;67:3512-7.
16. Fulda S, Debatin KM. Sensitization for anticancer druginduced apoptosis by the chemopreventive agent resveratrol. Oncogene. 2004;23:6702-11.
17. Fulda S, Debatin KM. Sensitization for anticancer drug-induced apoptosis by betulinic Acid. Neoplasia. 2005;7:162-70.
18. Custodio JB, Cardoso CM, Madeira VM, Almeida LM. Mitochondrial permeability transition induced by the anticancer drug etoposide. Toxicol In Vitro. 2001;15:265-70.
19. Gusman J, Malonne H, Atassi G. A reappraisal of the potential chemopreventive and chemotherapeutic properties of resveratrol. Carcinogenesis. 2001;22:1111-7.
20. Lu DY, Huang M, Xu CH, Yang WY, Hu CX, Lin LP et al. Anti-proliferative effects, cell cycle G2/M phase arrest and blocking of chromosome segregation by probimane and MST-16 in human tumor cell lines. BMC Pharmacol. 2005;5:11doi:10.1186/1471-2210-5-11.
21. Wallin A, Svanvik J, Holmlund B, Ferreud L, Sun XF. Anticancer effect of SN-38 on colon cancer cell lines with different metastatic potential. Oncol Rep. 2008;19:1493-8.
22. Souza V, Dong YB, Zhou HS, Zacharias W, McMasters KM. SW-620 cells treated with topoisomerase I inhibitor SN-38: gene expression profiling. J Transl Med. 2005;3:44:doi:1186/1479-5876-3-44.
23. te Poele RH, Joel SP. Schedule-dependent cytotoxicity of SN-38 in p53 wild-type and mutant colon adenocarcinoma cell lines. Br J Cancer 1999;81:1285-93.
24. Pei XH, Nakanishi Y, Takayama K, Bai F, Kawasaki M, Tsuruta N et al. Effect of CPT-11 in combination with other anticancer agents in lung cancer cells. Anticancer Drugs 1997;8:231-7.
25. van Ark-Otte J, Kedde MA, van der Vijgh WJ, Dingemans AM, Jansen WJ, Pinedo HM et al. Determinants of CPT-11 and SN-38 activities in human lung cancer cells. Br J Cancer 1998;77:2171-6.
26. Ohtsuka K, Inoue S, Kameyama M, Kanetoshi A, Fujimoto T, Takaoka K et al. Intracellular conversion of irinotecan to its active form, SN-38, by native carboxylesterase in human non-small cell lung cancer. Lung Cancer 2003;41:187-98.
27. Scaduto JRC, Grotyohann, LW. Measurement of mitochondrial membrane potential using fluorescent rhodamine derivatives Biophys J. 1999;76:469-77.
28. Kroemer G, Dallaporta B, Resche-Rigon M. The mitochondrial death/life regulator in apoptosis and necrosis. Annu Rev Physiol. 1998;60:619-42.
29. Auerbach O, Garfinkel L. The changing pattern of lung carcinoma. Cancer 1991;68:1973-7.
30. Tsai CM, Chang KT, Chen JY, Chen YM, Chen MH, Perng RP. Cytotoxic effects of gemcitabine-containing regimens against human non-small cell lung cancer cell lines which express different levels of p185neu. Cancer Res. 1996;56:794-801.
31. Radhakrishna Pillai G, Srivastava AS, Hassanein TI, Chauhan DP, Carrier E. Induction of apoptosis in human lung cancer cells by curcumin. Cancer Lett. 2004;208:163-70.
32. Herr I, Debatin KM. Cellular stress response and apoptosis in cancer therapy. Blood 2001;98:2603-14.
33. Lowe SWL, AW. Apoptosis in cancer. Carcinogenesis 2000;21:485-95.
34. Hengartner MO. The biochemistry of apoptosis. Nature 2000;407:770-6.
35. Debatin KM, Poncet D, Kroemer G. Chemotherapy: targeting the mitochondrial cell death pathway. Oncogene. 2002;21:8786-803.
36. van Loo GS X, van Gurp M, MacFarlane M, Martin SJ,; Vandenabeele P. The role of mitochondrial factors in apoptosis: a Russian roulette with more than one bullet. Cell Death Differ. 2002;9:1031-42.
37. Nicholson DW, Ali A, Thornberry NA, Vaillancourt JP, Ding CK, Gallant M et al. Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature. 1995;376:37-43.
38. Simbulan-Rosenthal CM, Rosenthal DS, Iyer S, Boulares AH, Smulson ME. Transient poly(ADP-ribosyl) ation of nuclear proteins and role of poly(ADP-ribose) polymerase in the early stages of apoptosis. J Biol Chem. 1998;273:13703-12.
39. Berger NA. Poly(ADP-ribose) in the cellular response to DNA damage. Radiat Res. 1985;101:4-15.
40. Dobashi Y, Takehana T, Ooi A. Perspectives on cancer therapy: cell cycle blockers and perturbators. Curr Med Chem. 2003;10:2549-58.
41. Saito Y, Yasunaga M, Kuroda J, Koga Y, Matsumura Y. Enhanced distribution of NK012, a polymeric micelleencapsulated SN-38, and sustained release of SN-38 within tumors can beat a hypovascular tumor. Cancer Sci. 2008;99:1258-64.